-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Invivyd, Inc. F/k/a Adagio Therapeutics, Inc. With Losses of $100,000 to Contact the Firm
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Invivyd, Inc. F/k/a Adagio Therapeutics, Inc. With Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - February 8, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. ("Invivyd" or "the Company") (NASDAQ: IVVD) (NASDAQ: ADGI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between November 29, 2021 and December 14, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before April 3, 2023.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at , or by email at bschall@schallfirm.com.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Invivyd's studies and analyses that it claimed to demonstrate ADG20's effectiveness against the Omicron variant were unreliable and ineffective. The Company's claims about the effectiveness of ADG20 were not supported by facts. In fact, ADG20 was 300 times less effective against Omicron as against prior variants of COVID-19. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Invivyd, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
Office: 310-301-3335
info@schallfirm.com
SOURCE:
The Schall Law Firm
To view the source version of this press release, please visit
Los Angeles, California--(Newsfile Corp. - February 8, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. ("Invivyd" or "the Company") (NASDAQ: IVVD) (NASDAQ: ADGI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
加利福尼亚州洛杉矶-(Newsfile Corp.-2023年2月8日)-全国性股东权利诉讼公司Schall律师事务所提醒投资者，一起针对因维德公司(Invivyd，Inc.)(“Invivyd”或“本公司”)(纳斯达克：IVVD)(纳斯达克：ADGI)的集体诉讼，指控其违反1934年证券交易法第10(B)和20(A)节以及美国证券交易委员会颁布的规则10b-5。
Investors who purchased the Company's securities between November 29, 2021 and December 14, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before April 3, 2023.
鼓励在2021年11月29日至2021年12月14日期间(首尾两日包括在内)购买本公司证券的投资者在2023年4月3日之前与本公司联系。
If you are a shareholder who suffered a loss, click here to participate.
如果您是蒙受损失的股东，请单击此处参与。
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at , or by email at bschall@schallfirm.com.
我们还鼓励您联系Schall律师事务所的Brian Schall，2049世纪公园东区，加州洛杉矶2460Suit2460，邮编：90067，电话：310-3013335，讨论您的免费权利。您也可以通过公司的网站或电子邮件bschall@schallffer.com联系我们。
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
在这种情况下，该课程尚未获得认证，在获得认证之前，您不会由律师代表。如果你选择不采取行动，你可以保持缺席班级成员的身份。
According to the Complaint, the Company made false and misleading statements to the market. Invivyd's studies and analyses that it claimed to demonstrate ADG20's effectiveness against the Omicron variant were unreliable and ineffective. The Company's claims about the effectiveness of ADG20 were not supported by facts. In fact, ADG20 was 300 times less effective against Omicron as against prior variants of COVID-19. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Invivyd, investors suffered damages.
根据起诉书，该公司向市场做出了虚假和误导性的陈述。Invivyd声称证明ADG20对奥密克戎变体有效的研究和分析是不可靠和无效的。该公司关于ADG20有效性的说法没有事实支持。事实上，与之前的奥密克戎变种相比，ADG20对新冠肺炎的效果要低300倍。基于这些事实，公司的公开声明在整个课程期间都是虚假的，具有重大误导性。当市场得知Invivyd的真相时，投资者蒙受了损失。
Join the case to recover your losses.
加入这个案子，挽回你的损失。
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
Schall律师事务所代表世界各地的投资者，专门处理证券集体诉讼和股东权利诉讼。
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
根据适用的法律和道德规则，本新闻稿在某些司法管辖区可能被视为律师广告。
CONTACT:
联系方式：
The Schall Law Firm
Brian Schall, Esq.,
Office: 310-301-3335
info@schallfirm.com
沙尔律师事务所
布莱恩·舒尔，Esq.
办公室：310-301-3335
邮箱：Info@schallFirm.com
SOURCE:
资料来源：
The Schall Law Firm
沙尔律师事务所
To view the source version of this press release, please visit
要查看本新闻稿的源版本，请访问
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧